Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

2023556 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 24, Issue 11, pp. 1181-1195

Field-Weighted Citation Impact: 143.28